Skin Cancer Epidemiology, Detection, and Management

Gandhi, Sumul; Kampp, Jeremy T.

doi:10.1016/j.mcna.2015.06.002

Cited by 132 publications

(95 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Basal cell carcinoma is the most common skin malignancy among the white population [1]. Tumor growth can be locally destructive, but metastases are very rare.…”

Section: Introductionmentioning

confidence: 99%

Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma

et al. 2018

View full text Add to dashboard Cite

Background: Metastatic basal cell carcinoma is rare and the prognosis is poor, with a lack of established treatment options for patients progressing on or after treatment with inhibitors of the hedgehog signaling pathway. Case Report: A man with pulmonary metastases of a basal cell carcinoma progressing after treatment with sonidegib and vismodegib was started on treatment with the anti-PD-1 antibody pembrolizumab. Upon treatment, rapid clinical improvement occurred, and after 5 cycles, the computed tomography scan showed near-complete remission of all tumor lesions. The tumor cells showed the absence of PD-L1 expression. Discussion: We report the first case of a patient with metastatic basal cell carcinoma experiencing an exceptional response to treatment with pembrolizumab in the absence of PD-L1 expression on the tumor cells. Immune checkpoint inhibition seems a promising treatment strategy for metastatic basal cell carcinoma. Our case suggests that the lack of PD-L1 expression does not rule out potential benefit from checkpoint inhibitor treatment.

show abstract

“…Basal cell carcinoma is the most common skin malignancy among the white population [1]. Tumor growth can be locally destructive, but metastases are very rare.…”

Section: Introductionmentioning

confidence: 99%

Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…1 These cutaneous tumours are usually indolent and cured by local resection. However, basal cell carcinomas can be locally destructive; rarely, they metastasise to distant organs.…”

Section: Introductionmentioning

confidence: 99%

Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy

et al. 2016

View full text Add to dashboard Cite

Metastatic basal cell carcinomas are rare malignancies harbouring Hedgehog pathway alterations targetable by SMO antagonists (vismodegib/sonidegib). We describe, for the first time, the molecular genetics and response of a patient with Hedgehog inhibitor-resistant metastatic basal cell carcinoma who achieved rapid tumour regression (ongoing near complete remission at 4 months) with nivolumab (anti-PD1 antibody). He had multiple hallmarks of anti-PD1 responsiveness including high mutational burden (> 50 mutations per megabase; 19 functional alterations in tissue next-generation sequencing (NGS; 315 genes)) as well as PDL1/PDL2/JAK2 amplification (as determined by both tissue NGS and by analysis of plasma-derived cell-free DNA). The latter was performed using technology originally developed for the genome-wide detection of sub-chromosomal copy-number alterations (CNAs) in noninvasive prenatal testing and showed numerous CNAs including amplification of the 9p24.3-9p22.2 region containing PD-L1, PD-L2 and JAK2. Of interest, PD-L1, PD-L2 and JAK2 amplification is a characteristic of Hodgkin lymphoma, which is exquisitely sensitive to nivolumab. In conclusion, selected SMO antagonist-resistant metastatic basal cell carcinomas may respond to nivolumab based on underlying molecular genetic mechanisms that include PD-L1 amplification and high tumour mutational burden.

show abstract

“…Skin cancer is the most common malignancy in North America, when considered as a single entity (1). The various forms of cutaneous malignancies include malignant melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC).…”

mentioning

confidence: 99%

Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review

Nguyen

Detty

Agrawal

2017

View full text Add to dashboard Cite

show abstract

Skin Cancer Epidemiology, Detection, and Management

Cited by 132 publications

References 19 publications

Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma

Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma

Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy

Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review

Contact Info

Product

Resources

About